Non Small Cell Lung Cancer Clinical Trials in Houston, Texas

83 studies are recruiting for non small cell lung cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 4

1. EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

   This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas

   Locations

   5 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT05467748 on ClinicalTrials.gov

2. Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery

   The goal of the trial is to test the usability, feasibility and acceptability of an unsupervised, appbased yoga program for participants undergoing thoracic RT and their caregivers.

   Stage

   Not phased

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06919874 on ClinicalTrials.gov

3. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

   This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   The University of Texas MD Anderson Cancer Center (site 127), Houston, Texas

   Locations

   15 in total

   Run by

   VM Oncology, LLC

   See if you can join NCT03556228 on ClinicalTrials.gov

4. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Houston, Texas

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

5. A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

   The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Hospital, Houston, Texas

   Locations

   2 in total

   Run by

   Shanghai Henlius Biotech

   See if you can join NCT06907615 on ClinicalTrials.gov

6. BostonGene and Exigent Genomic INsight Study

   The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Oncology Consultants, Houston, Texas

   Locations

   7 in total

   Run by

   BostonGene

   See if you can join NCT06272864 on ClinicalTrials.gov

7. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

   This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Consultants, P.A., Houston, Texas

   Locations

   13 in total

   Run by

   GV20 Therapeutics

   See if you can join NCT05669430 on ClinicalTrials.gov

8. A Study of IBI363 in Subjects with Advanced Solid Malignancies

   This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center-University of Texas, Houston, Texas

   Locations

   9 in total

   Run by

   Innovent Biologics (Suzhou) Co. Ltd.

   See if you can join NCT06281678 on ClinicalTrials.gov